Long‐Term Outcomes in Stiff Person Spectrum Disorder
European Journal of Neurology · 2026
DOI: 10.1111/ene.70609 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Georgios Mangioris und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Stiff-Person Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Background
Long‐term outcome data for stiff person spectrum disorder (SPSD) remain limited and sustained response to treatment varies.
Methods
In this retrospective cohort study, we included patients with probable or definite SPSD (Mayo Clinic criteria), evaluated at Mayo Clinic (12/1995‐07/2024) with ≥ 5 years of follow‐up after diagnosis. Primary outcome measures included the modified Rankin scale (mRS) and use of gait aids.
Results
Fifty‐four patients were included, 41 (76%) were female; median age at onset was 45 years (16–78). Most were antibody‐positive (51 [94%]), with high‐titer (serum, ≥ 20 nmol/L) GAD65‐IgG in 45 (83%). Nine patients had a stiff‐limb presentation (17%). The median interval from onset to diagnosis was 2 years (0–34), and median follow‐up was 9 years (5–26). Most patients (46 [85%]) received immune therapy; 37 (82%) reported improvement. All patients had significant impairment (mRS ≥ 2) at nadir, with 31 (57%) losing functional independence (mRS ≥ 3) and 40 (75%) requiring bilateral gait assistance. The median time from onset to nadir was 6 years (0–39). At last follow‐up, most (37 [69%]) were functionally independent (mRS ≤ 2), including 8 (15%) with minimal restrictions (mRS ≤ 1). Bilateral gait assistance was needed in 22 (41%). Among 40 patients with ≥ 10 years of follow‐up, 22 (56%) had an mRS ≤ 2 and 25 (63%) required a gait aid at last follow‐up. Poor outcome in this population was associated with bilateral gait assistance at nadir and older age ( p < 0.05).
Conclusions
Although over half of SPSD patients lose functional independence at disease nadir, many regain independence and achieve well‐controlled symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Center for Multiple Sclerosis & Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Division of Neurology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
ORCID-Profile: Nisa Vorasoot, Anastasia Zekeridou
Förderung
- NINDS NIH HHS
Zitieren
APA
Mangioris, G., McKeon, A., Bower, J. H., Vorasoot, N., Dubey, D., Flanagan, E. P., Pittock, S. J., & Zekeridou, A. (2026). Long‐Term Outcomes in Stiff Person Spectrum Disorder. European Journal of Neurology. https://doi.org/10.1111/ene.70609
Vancouver
Mangioris G, McKeon A, Bower JH, Vorasoot N, Dubey D, Flanagan EP, et al. Long‐Term Outcomes in Stiff Person Spectrum Disorder. European Journal of Neurology. 2026. doi:10.1111/ene.70609
BibTeX
@article{Mangioris2026,
author = {Mangioris, Georgios and McKeon, Andrew and Bower, James H and Vorasoot, Nisa and Dubey, Divyanshu and Flanagan, Eoin P and Pittock, Sean J and Zekeridou, Anastasia},
title = {Long‐Term Outcomes in Stiff Person Spectrum Disorder},
journal = {European Journal of Neurology},
year = {2026},
doi = {10.1111/ene.70609}
}
EUVIMED